UF-010

Research use only, not for human use.

A potent and selective inhibitor of class I HDACs.

A potent and selective inhibitor of class I HDACs with IC50s of 0.5/0.1/0.06/1.5/9.1/15.3/44.5 uM for HDAC1/2/3/8/6/10/11 respectively; shows no effect on HDAC4/5/7/9(>100 uM); induces the accumulation of protein acetylation and inhibits proliferation of NCI-60 panel of cancer cell lines (mean GI50=2.94 uM); a competitive with a fast-on/slow-off HDAC-binding mechanism.

Cell Cytotoxicity Assay Cell Line:B16F10 cells, MCF-7 cells, A549 cells, 4T1 cells, HEK-293 cells and HCEC cells Concentration:10 μM, 100 μM Incubation Time:72 h Result:Showed IC50 values of 2.41 μM for B16F10 cells, 20.81 μM for A549 cells, 17.93 μM for MCF-7 cells, 8.40 μM for 4T1 cells, 98.52 μM for HEK-293 cells, 95.4 μM for HCEC cells.

Animal Model:postoperative cognitive dysfunction (POCD) miceDosage:15 mg/kg Administration:Intraperitoneal injection (i.p.)Result:Weakened the infiltration of CD4+ T cells and NK cells in hippocampal tissues.Reduced inflammatory parameters in serum and hippocampal tissues, such as interleukin 6 (IL-6), C-reactive protein (CRP), and tumor necrosis factor alpha (TNF-α) levels.Activated the NF-κB/p65, JAK/STAT and TLR/MyD88 pathways.Animal Model:4T1-Luc tumor-bearing mouse modelDosage:15 mg/kg Administration:Intraperitoneal injection (i.p.)Result:Inhibited the tumor growth rate percentage to 55.56, 38.36, 39.52% at days 7, 14, and 21.Induced high levels of ROS generation, causing apoptosis-mediated tumor cell death.

UF010 | UF 010

Cell Cycle/DNA Damage

HDAC

HDAC

Cancer

——

537672-41-6

271.1536

C11H15BrN2O

>98% (HPLC)

10 mM in DMSO

O=C(NNCCCC)C1=CC=C(Br)C=C1

Benzoic acid, 4-bromo-, 2-butylhydrazide

(-20℃)

With Ice Pack

≥ 2 years